nach oben

Quality of Life Research

Erschienen in:

01.03.2012

Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials

verfasst von: Dennis A. Revicki, Donald Stull, Margaret Vernon, Michael Rader, Dianne Tomita, Hema N. Viswanathan

Erschienen in: Quality of Life Research | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This analysis examined the effects of darbepoetin alfa on hemoglobin and fatigue outcomes in patients with cancer using latent growth curve modeling (LGM).

Methods

Data from 4 clinical trials of darbepoetin alfa in lung cancer (2 studies; n = 547; n = 288), lymphoproliferative malignancies (n = 339), and non-myeloid malignancies (n = 320) were analyzed separately. Fatigue was assessed using the FACT-Fatigue (FACT-F) scale. Effects of darbepoetin alfa on changes in hemoglobin and FACT-F scores were evaluated using LGM, controlling for age, gender, Eastern Cooperative Oncology Group performance status, health status, and total transfusions.

Results

Patients receiving darbepoetin alfa had higher rates of change in hemoglobin (standardized regression coefficient [\( \hat{\beta } \)] = 0.30 to 0.53, all P < 0.05) than placebo. Patients with greater rates of change in hemoglobin reported improvements in fatigue outcomes (\( \hat{\beta } \) = 0.28 to 0.59, all P < 0.05). The total standardized effect of darbepoetin alfa on fatigue outcomes corresponded to a mean change of 0.9 to 3.5 points in FACT-F scores, with one trial demonstrating changes exceeding the minimal important difference of 3 points.

Conclusions

Darbepoetin alfa improved hemoglobin which was associated with improved fatigue across the 4 trials. Clinically, meaningful improvement in fatigue was seen in 2 trials. More complex statistical analysis models of treatment may assist in understanding the effects of erythropoiesis-stimulating agents on patient-reported outcomes.

Ashbury, F. D., Findlay, H., Reynolds, B., & McKerracher, K. (1998). A Canadian survey of cancer patients’ experiences: Are their needs being met? Journal of Pain and Symptom Management, 16(5), 298–306.PubMedCrossRef

Cella, D., Davis, K., Breitbart, W., & Curt, G. (2001). Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology, 19(14), 3385–3391.PubMed

Cella, D., Kallich, J., McDermott, A., & Xu, X. (2004). The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Annals of Oncology, 15(6), 979–986.PubMedCrossRef

Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the fatigue coalition. Oncologist, 5(5), 353–360.PubMedCrossRef

Irvine, D., Vincent, L., Graydon, J. E., Bubela, N., & Thompson, L. (1994). The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nursing, 17(5), 367–378.PubMedCrossRef

Stone, P., Richards, M., A’Hern, R., & Hardy, J. (2000). A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Annals of Oncology, 11(5), 561–567.PubMedCrossRef

Cella, D., Dobrez, D., & Glaspy, J. (2003). Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Annals of Oncology, 14(4), 511–519.PubMedCrossRef

Chang, J., Couture, F., Young, S., McWatters, K. L., & Lau, C. Y. (2005). Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. Journal of Clinical Oncology, 23(12), 2597–2605.PubMedCrossRef

Crawford, J., Cella, D., Cleeland, C. S., Cremieux, P. Y., Demetri, G. D., Sarokhan, B. J., et al. (2002). Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 95(4), 888–895.PubMedCrossRef

10.

Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001). Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19(11), 2875–2882.PubMed

11.

Gabrilove, J. L., Perez, E. A., Tomita, D. K., Rossi, G., & Cleeland, C. S. (2007). Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 micro g every 2 weeks. Cancer, 110(7), 1629–1640.PubMedCrossRef

12.

Glaspy, J. A., Jadeja, J. S., Justice, G., Kessler, J., Richards, D., Schwartzberg, L., et al. (2002). Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer, 87(3), 268–276.PubMedCrossRef

13.

Johansson, J. E., Wersall, P., Brandberg, Y., Andersson, S. O., & Nordstrom, L. (2001). Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer—a randomized study. Scandinavian Journal of Urology and Nephrology, 35(4), 288–294.PubMedCrossRef

14.

Kallich, J. D., Tchekmedyian, N. S., Damiano, A. M., Shi, J., Black, J. T., & Erder, M. H. (2002). Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park), 16(9 Suppl 10), 117–124.

15.

Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., & Rapoport, B. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19(11), 2865–2874.PubMed

16.

Osterborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., et al. (2002). Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. Journal of Clinical Oncology, 20(10), 2486–2494.PubMedCrossRef

17.

Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., et al. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Journal of Clinical Oncology, 26(1), 132–149.PubMedCrossRef

18.

Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A. B., et al. (2003). Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer, 39(14), 2026–2034.PubMedCrossRef

19.

Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M. H., Schipperus, M. R., Juvonen, E., et al. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. British Journal Haematology, 122(3), 394–403.CrossRef

20.

Littlewood, T. J., Kallich, J. D., San Miguel, J., Hendricks, L., & Hedenus, M. (2006). Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. Journal of Pain and Symptom Management, 31(4), 317–325.PubMedCrossRef

21.

Pirker, R., Ramlau, R. A., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., et al. (2008). Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Journal of Clinical Oncology, 26(14), 2342–2349.PubMedCrossRef

22.

Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., et al. (2002). Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94(16), 1211–1220.PubMedCrossRef

23.

Minton, O., Stone, P., Richardson, A., Sharpe, M., & Hotopf, M. (2008). Drug therapy for the management of cancer related fatigue. Cochrane Database System Review, (1), CD006704.

24.

Ross, S. D., Allen, I. E., Henry, D. H., Seaman, C., Sercus, B., & Goodnough, L. T. (2006). Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clinical Therapy, 28(6), 801–831.CrossRef

25.

Bollen, K., & Curran, P. (2006). Latent curve models: A structural equation perspective. Hoboken, NJ: Wiley.

26.

Duncan, T., Duncan, S., & Strycker, L. (2006). An introduction to latent variable growth curve modeling: Concepts, issues, and applications. Mahwah, NJ: Lawrence Erlbaum Associates.

27.

Kline, R. B. (2010). Principles and practice of structural equation modeling. New York: Guilford Press.

28.

Stull, D. E. (2008). Analyzing growth and change: Latent variable growth curve modeling with an application to clinical trials. Quality of Life Research, 17(1), 47–59.PubMedCrossRef

29.

Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol group. Annals of Medicine, 33(5), 337–343.PubMedCrossRef

30.

Cella, D. (1997). The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Seminars in Hematology, 34(3 Suppl 2), 13–19.PubMed

31.

Cella, D., Eton, D. T., Lai, J. S., Peterman, A. H., & Merkel, D. E. (2002). Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24(6), 547–561.PubMedCrossRef

32.

Wothke, W. (2000). Longitudinal and multi-group modeling with missing data. In T. D. Little, K. Schnabel, & J. Baumert (Eds.), Modeling longitudinal and multilevel data: Practical issues, applied approaches, and specific examples. Mahwah, NJ: Lawrence Erlbaum Associates.

33.

Muthén, L. K., & Muthén, B. O. (1998–2007). Mplus user’s guide. Los Angeles, CA: Muthén & Muthén.

34.

Browne, M., & Cudeck, R. (1993). Alternative ways of assessing model fit. In K. Bollen & J. Long (Eds.), Testing structural equation models (pp. 136–162). Newbury Park, CA: Sage.

35.

Marsh, H. W., Hau, K. T., & Wen, Z. (2004). In search of golden rules: comment on hypothesis-testing approaches to setting cutoff values for fit indexes and dangers of overgeneralizing Hu and Bentler’s (1999) findings. Structural Equation Modeling, 11, 320–341.CrossRef

36.

Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102–109.PubMedCrossRef

Titel: Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials
verfasst von: Dennis A. Revicki
Donald Stull
Margaret Vernon
Michael Rader
Dianne Tomita
Hema N. Viswanathan
Publikationsdatum: 01.03.2012
Verlag: Springer Netherlands
Erschienen in: Quality of Life Research / Ausgabe 2/2012
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-011-9946-z

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Rasch analysis in the development of a simplified version of the national eye institute visual-function questionnaire-25 for utility estimation

Individual interviews and focus groups in patients with rheumatoid arthritis: a comparison of two qualitative methods

Differences in quality of life of hemodialysis patients between dialysis centers

Development of the PedsQL™ sickle cell disease module items: qualitative methods

Use of the Distress Thermometer to discern clinically relevant quality of life differences in women with breast cancer

Verification of the psychometric properties of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 palliative (EORTCQLQ-C15-PAL)